Anti-oxidant therapy for the treatment of coronary artery disease

Bibliography

• MURRAY C, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349:1269–1276.
   PubMed Web of Science ®Google Scholar
• ROSAMOND WD, CHAMBLESS L, FOLSOM A et al.: Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl. J. Med. (1998) 339:861–867.
   PubMed Web of Science ®Google Scholar
• TUNSTALL-PEDOE H, KUULASMAA K, MAHONEN M et al: Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality:10 year results from 37 WHO MONICA Project populations. Lancet (1999) 353:1547–1557.
   PubMed Web of Science ®Google Scholar
• •A major study quantifying the incidence of coronary artery disease.
   Google Scholar
• MCMENEMY M: Coronary heart disease still dropping in the UK. Lancet (1999) 353:1598.
   Web of Science ®Google Scholar
• FIBRINOLYTIC THERAPY TRIALISTS (FTT) COLLABORA-TIVE GROUP: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet (1994) 343:311–322.
   PubMed Web of Science ®Google Scholar
• LANDRAY MJ, NUTTALL SL, LYDAKIS C et al: Oxidativestress after thrombolysis. Lancet (1998) 352:960.
   PubMed Web of Science ®Google Scholar
• •An interesting study demonstrating the importance of free radical damage in patients who have had an acute myocar-dial infarction and the importance of reperfusion as a cause of oxidative stress
   Google Scholar
• VACCARINO V, PARSONS L, EVERY NR et al.: Sex-based differences in early mortality after myocardial infarc-tion. N Engl. J. Med. (1999) 341:217–225.
   PubMed Web of Science ®Google Scholar
• NORRIS RM: Fatality outside hospital from acute coronary events in three British health districts, 1994-5. Br. Med. J. (1998) 316:1065–1070.
   PubMed Web of Science ®Google Scholar
• •A paper documenting the large number of deaths from coronary artery disease, which occur outside hospital
   Google Scholar
• KANNEL WB, CUPPLES LA, D'AGOSTINO RB et al.: Hypertension, antihypertensive treatment and sudden coronary death: the Framingham study. Hypert. (1988) II\(Suppl. 2):45–50.
   Google Scholar
• MEDICAL RESEARCH COUNCIL WORKING PARTY: MRC trial of treatment of mild hypertension: Principal results. Br. Med. J. (1985) 291:97–104.
   PubMed Web of Science ®Google Scholar
• OLSSON G, TUOMILEHTO J, BERGLUND G et al.: Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY study. Am. J. Hypert. (1991) 4:151–158.
   PubMed Web of Science ®Google Scholar
• SHEP CO-OPERATIVE RESEARCH GROUP: Prevention ofstroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA (1991) 265:3255–3264.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, LINDHOLM LH, HANSSON L et al.: Morbidityand mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension). Lancet (1991) 338:1281–1285.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, FAGARD R, THUS L et al: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet (1997) 350:757–764.
   PubMed Web of Science ®Google Scholar
• NUTTALL SL, TOESCU V, KENDALL MJ: The incidence of sudden death in post-MI 6-blocker trials. J. Clin. Pharm. Ther. (1999) (In press).
   Google Scholar
• ROQUE. F, AMUCHASTEGU, LM, LOPEZ MORILLOS MA et al.: Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocar-dial infarction. Circulation (1987) 76(3)610–617.
   Google Scholar
• NORWEGIAN MULTICENTRE STUDY GROUP: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl. J. Med. (1981) 304:801–807.
   PubMed Web of Science ®Google Scholar
• •The first major post-myocardial infraction beta-blocker study. It showed that timolol markedly reduced the risk of sudden death
   Google Scholar
• HANSTEEN V, MOINICHEN E, LORENTSEN E et al.: Oneyear's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br. Med. J. (1982) 284:155–160.
   PubMed Web of Science ®Google Scholar
• 13 BLOCKER HEART ATTACK RESEARCH GROUP: A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA (1982) 247:1707–1713.
   Google Scholar
• KAUL UA, VERMA R, GARG KC: Early intervention withpropranolol after acute myocardial infarction:serial left ventricular function determined by M-mode and cross-sectional echocardiography. Int. J. Cardiol. (1988) 21:301–310.
   PubMed Web of Science ®Google Scholar
• OLSSON G, WIKSTRAND J, WARNOLD I et al.:Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur. Heart J. (1992) 13:28–32.
   PubMed Web of Science ®Google Scholar
• •A key paper documenting the impact of metrprolol on risk of sudden death in post-myocardial infarct patients
   Google Scholar
• CIBIS-II INVESTIGATORS AND COMMITTEES: The cardiac insufficiency Bisoprolol Study II (CIBIS-I0a randomised trial. Lancet (1999) 353:9–13.
   PubMed Web of Science ®Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/XLin chronic heart failure: metoprolol CR/XL random-ised intervention trial in congestive heart failure (MERIT-HF). Lancet (1999) 353:2001–2007.
   PubMed Web of Science ®Google Scholar
• •The most recent and largest study showing that beta-blockers significantly reduce mortality in patients with heart failure
   Google Scholar
• COLLINS R, PETO R, MACMAHON S etal.: Blood pressure, strokes and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 335:827–838.
   Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS G et al. Benefits of intensive blood pressure lowering and acetylsalicylic acid in hypertensive patients. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• •A large study showing the benefits of treating hypertension and the added benefits of giving aspirin in addition to antihypertensive therapy
   Google Scholar
• SHEPHERD J, COBEE SM, FORD I et al.: Prevention ofcoronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, MCGEE DL: Diabetes and cardiovasculardisease. The Framingham Study. JAMA (1979) 241:2035–2038.
   PubMed Web of Science ®Google Scholar
• BARRET-CONNOR E, WINGARD D: Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am. J. Epidemiol. (1983) 118:489–496.
   PubMed Web of Science ®Google Scholar
• TUNSTALL-PEDOE H: Myth and paradox of coronary risk and the menopause. Lancet (1998) 351:1425–1427.
   PubMed Web of Science ®Google Scholar
• KUSHI LH, FOLSOM AR, PRINEAS RJ et al.: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl. J. Merl. (1996) 334:1156–1162.
   PubMed Web of Science ®Google Scholar
• COLLINS R, PETO R, BAIGENT C et al.: Aspirin, Heparin and fibrinolytic therapy in suspected acute myocar-dial infarction. N Engl. J. Merl. (1997) 336:847–860.
   PubMed Web of Science ®Google Scholar
• KENNEDY HL, ROSENSON RS: Physician use of beta-adrenergic blocking therapy: a changing perspective. J. Am. Coll. Cardiol. (1995) 26:547–552.
   PubMed Web of Science ®Google Scholar
• MACMAHON S, PETO R et al: Epidemiology blood pressure, stroke, and coronary heart disease part 1 prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 335:765–774.
   PubMed Web of Science ®Google Scholar
• KENDALL MJ, LYNCH KP, HJALMARSON A et al.: 8-Blockers and sudden cardiac death. Ann. Intern. Merl. (1995) 123:358–367.
   PubMed Web of Science ®Google Scholar
• •A useful review setting out the evidence that beta-blockers have a key role in reducing sudden death in coronary artery disease.
   Google Scholar
• KENDALL MJ: Hypertension in the elderly. Pharm. Pharmacol Lett. (1998) 8(2):9.
   Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• •The first major study demonstrating that marked reduction in plasma cholesterol levels has a major impact on mortality in post-infarct patients
   Google Scholar
• SACKS F, ROULEAU J, MOYE LA et al.: Baseline character- istic in the cholesterol and recurrent events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am. J. Cardiol (1995) 75:621–623.
   PubMed Web of Science ®Google Scholar
• THE LIPID STUDY GROUP Prevention of cardiovas- cular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Merl. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• WEST OF SCOTLAND CORONARY PREVENTION GROUP:West of Scotland Coronary Prevention Study: identifi-cation of high-risk groups and comparison with other cardiovascular intervention trials. Lancet (1996) 348:1339–1342.
   PubMed Web of Science ®Google Scholar
• HAFFNER S, LEHTO S, RONNEMAA T et al: Mortalityfrom coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl. J. Med. (1998) 339:229–234.
   PubMed Web of Science ®Google Scholar
• •The first primary prevention study showing that reducing the cholesterol in male patients not known to have coronary heart disease reduced the risk of subsequent coronary events
   Google Scholar
• MALMBERG K, NORHAMMAR A, WEDEL H et al.: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarc-tion. Circulation (1999) 99:2626–2632.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J. (1998) 317:703–713.
   PubMed Web of Science ®Google Scholar
• NUTTALL SL, DUNNE F, KENDALL MJ et al.: Age-independent oxidative stress in elderly patients with NIDDM. Q. J. Med. (1998) 92:33–38.
   Google Scholar
• THEROUX P: Antiplatelet drugs in the acute phase of myocardial infarction. Eur. Heart J. Suppl. (1999) 1 (Suppl. F):F29–F33.
   Google Scholar
• PATRONO C: Aspirin as an antiplatelet drug. N Engl. J. Merl. (1994) 330:1287–1294.
   PubMed Web of Science ®Google Scholar
• COUMADIN ASPIRIN REINFARCTION STUDY (CARS) INVESTIGATORS: Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet (1997) 350:389–396.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• THE PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT (PRISM) STUDY INVESTIGA-TORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl. J. Merl. (1998) 338:1498–1505.
   PubMed Web of Science ®Google Scholar
• THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL (CAST): Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppresion after myocardial infarction. N Engl. J. Med. (1989) 321:406–412.
   PubMed Web of Science ®Google Scholar
• •An important study which showed that antiarrhythmic drugs increased rather than decreased the mortality from arrhythmias. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(11)
   Google Scholar
• JULIAN DG, CAMM AJ, FRANGIN G et al.: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocar-dial infarction:EMIAT. Lancet (1997) 349:667–674.
   PubMed Web of Science ®Google Scholar
• CAIRNS JA, CONNOLLY SJ, ROBERTS R eta].: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet (1997) 349:675–682.
   Google Scholar
• BARRETT-CONNOR E: Hormone Replacement Therapy. Br. Med. J. (1998) 317:457–461.
   PubMed Web of Science ®Google Scholar
• CLINICAL SYNTHESIS PANEL ON HRT: Hormone replace-ment therapy. Lancet (1999) 354:152–155.
   PubMed Web of Science ®Google Scholar
• RICH-EDWARDS JW, MANSON JE, HENNEKENS CH et al.: The primary prevention of coronary heart disease in women. N Engl. J. Med. (1995) 332:1758–1766.
   PubMed Web of Science ®Google Scholar
• PETO R: Smoking and death: the past 40 years and the next 40. Br. Med. J. (1994) 309:937–939.
   PubMed Web of Science ®Google Scholar
• PRESCOTT E, HIPPE M, SCHNOHR P et al.: Smoking and risk of myocardial infarction in women and men; longitudinal population study. Br. Med. J. (1998) 316:1043–1047.
   PubMed Web of Science ®Google Scholar
• SHAPER AG, WANNAMETHEE GS, WALKER M: Body weight: implications for the prevention of coronary heart disease, stroke and diabetes mellitus in a cohort study of middle aged men. Br. Med. J. (1997) 314:1311–1317.
   PubMed Web of Science ®Google Scholar
• HARRIS TB, LAUNER LJ, MADANS J et al: Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. Br. Med. J. (1997) 314:1791–1794.
   PubMed Web of Science ®Google Scholar
• POWELL K & PRATT M: Physical activity and health. Br. Med. J. (1996) 313:126–127.
   PubMed Web of Science ®Google Scholar
• EAGLES C, GULATI R & MARTIN U: Non-pharmacological modification of cardiac risk factors: part 1. J. Clin. Pharm. Ther. (1996) 21:289–296.
   PubMed Web of Science ®Google Scholar
• ZINO S, SKEAFF M, WILLIAMS S et al.: Randomised controlled trial of effect of fruit and vegetable consumption on plasma concentrations of lipids and antioxidants. Br. Med. J. (1997) 314:1787–1791.
   PubMed Web of Science ®Google Scholar
• MARTIN U, EAGLES C: Non-pharmacological modifica-tion of cardiac risk factors: part 2. The role of diet. J. Pharm. Ther. (1997) 22:99–108.
   Web of Science ®Google Scholar
• GREENBERG ER, BARON JA, KARAGAS MR et al.: Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA (275) 275:699–703.
   Google Scholar
• MAXWELL SRJ, LIP GYH: Free radicals and antioxidants in cardiovascular disease. Br. J. Clin. Pharmacol. (1997) 44:307–317.
   PubMed Web of Science ®Google Scholar
• DIAZ MN, FREI B, VITA JA et al.: Antioxidants and athero-sclerotic heart disease. N. Engl. J. Med. (1997) 337:408–415.
   PubMed Web of Science ®Google Scholar
• •A useful review of anti-oxidants and atherosclerosis.
   Google Scholar
• CURRY SJ, GROTHAUS LC, MCAFEE T et al. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organi-zation. N Engl. J. Med. (1998) 339:673–679.
   PubMed Web of Science ®Google Scholar
• HE J, VUPPUTURI S, ALLEN K et al.: Passive smoking and the risk of coronary heart disease - a meta-analysis of epidemiologic studies. N. Engl. J. Med. (1999) 340:920–926.
   PubMed Web of Science ®Google Scholar
• BAILAR JC: Passive smoking, coronary heart disease, and meta-analysis. N Engl. J. Med. (1999) 340:958–959.
   PubMed Web of Science ®Google Scholar
• GUNNELL DJ, DAVEY SMITH G: Weight, weight gain and coronary heart disease mortality. Eur. Heart J. (1999) 20(0246–248.
   PubMed Web of Science ®Google Scholar
• ROSENGREN A, WEDEL H, WILHELMSEN L: Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. Eur. Heart J. (1999) 20(0269–277.
   PubMed Web of Science ®Google Scholar
• KEY TJA, THOROGOOD M, APPLEBY PN et al: Dietary habits and mortality in 11000 vegetarians and health conscious people: results of a 17 year follow up. Br. Med. J. (1996) 313:775–779.
   PubMed Web of Science ®Google Scholar
• KROMHOUT D & DE LEZENNE COULANDER C: Diet prevalence and 10 year mortality from coronary heart disease in 871 middle-aged men: The Zutphen Study. Am. J. Epidemic)]. (1984) 119:733–741.
   PubMed Web of Science ®Google Scholar
• DE LORGERIL M, SALEN P, MARTIN J-L eta].: Mediterra-nean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarc-tion. Final report of the Lyon Diet Heart Study. Circula-tion (1999) 99:779–785.
   Google Scholar
• RENAUD S, DE LOGERIL M: Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet (1992) 339:1523–1526.
   PubMed Web of Science ®Google Scholar
• •A key paper in the history of anti-oxidants
   Google Scholar
• HERTOG MGL: Flavonols in wine and tea and preven-tion of coronary heart disease. In: Polyphenols 96 Vercauteren J, Cheze C, Triaud J (Eds.) Paris, INRA (1998):117–131. .
   Google Scholar
• IMAI K, NAKACHI K: Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Br. Med. J. (1995) 310:693–696.
   PubMed Web of Science ®Google Scholar
• SESSO HD, GAZIANO JM, BURING JE eta].: Coffee and tea intake and the risk of myocardial infarction. Am. J. Epidemiol (1999) 149:162–167.
   Google Scholar
• STENSVOLD I, TVERDAL A, SOLVOLL K et al.: Tea consumption, relationship to cholesterol, blood pressure, and coronary and total mortality. Prey. Med. (1992) 21:546–553.
   PubMed Web of Science ®Google Scholar
• SOLEAS GJ, DIAMANDIS EP, GOLDBERG DM: Wine as a biological fluid: history, production and role in disease prevention. J. Lab. Gin. Anal. (1997) 11:287–313.
   PubMed Web of Science ®Google Scholar
• HERTOG MG, KROMHOUT D, ARAVANIS C et al.: Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med. (1995) 155:381–386.
   PubMed Web of Science ®Google Scholar
• GRAMENZI A, GENTILE A, FASOLI M et al.: Associationbetween certain foods and risk of acute myocardial infarction in women. Br. Med. J. (1990) 300:771-773. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(11)
   Google Scholar
• GAZIANO JM, MANSON JE, BRANCH LG et al.: A prospec-tive study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann. Epidemiology (1995) 5:255–260.
   PubMedGoogle Scholar
• HERTOG MGL, FESKENS EJM, HOLLMAN PCH et al.: Dietary anti-oxidant flavonoids and risk of coronary artery disease: the Zutphen Elderly Study. Lancet (1993) 342:1007–1011.
   PubMed Web of Science ®Google Scholar
• Free Radicals in Biology and Medicine 2nd Edition. Halliwell B, Gutteridge JMC (Eds.) (1989) Oxford University Press, Oxford (1989).
   Google Scholar
• SCHRAUFSTATTER IU, BROWNE K, HARRIS A et al.: Mechanisms of hypochlorite (HOC) injury of target cells. J. Clin. Invest. (1990) 85:554–562.
   PubMed Web of Science ®Google Scholar
• GREENWALD RA, MOY WW: Effect of oxygen-derivedfree radicals on hyaluronic acid. Arthritis and Rheuma-tism (1980) 23:455–463.
   PubMed Web of Science ®Google Scholar
• ARUOMA OI, HALLIWELL B, DIZDAROGLU M: Iron ion-dependent modification of bases in DNA by the superoxide radical generating system hypoxan-thine /xanthine oxidase. J. Biol. Chem. (1989) 264:13024–13028.
   PubMed Web of Science ®Google Scholar
• SCHRAUFSTATTER IU, HINSHAW DB, HYSLOP PA et al.: Oxidant injury of cells: DNA strand breaks activate polyadenosine diphosphate-ribose-polymerase and lead to depletion of nicotinamide adenine dinucleo-tide. J. Clin. Invest. (1986) 77:1312–1320.
   PubMed Web of Science ®Google Scholar
• BUETTNER, GR: The pecking order of free radicals and anti-oxidants: lipid peroxidation, a-tocopherol, and ascorbate. Arch. Biochem. Biophys. (1993) 300:535–543.
   PubMed Web of Science ®Google Scholar
• GUTTERIDGE, JM: Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem. (1995) 41:1819–1828.
   PubMed Web of Science ®Google Scholar
• DE BONO DP: Free radicals and antioxidants invascular biology: the roles of reaction kinetics, environment and substrate turnover. Q. J. Med. (1994) 87:445–453.
   Google Scholar
• NUTTALL SL, MARTIN U, SINCLAIR AJ et al.: Glutathione: in sickness and health. Lancet (1998) 351:645–646.
   PubMed Web of Science ®Google Scholar
• GUTTERIDGE JMC: Free radicals in disease processes: a compilation of cause and consequence. Free Radic. Res. Commun. (1993) 19:141–158.
   PubMedGoogle Scholar
• BULKLEY GB: Free radicals and other reactive oxygen metabolites: clinical relevance and the therapeutic efficacy of antioxidant therapy. Surgery (1993) 113:479–483.
   PubMed Web of Science ®Google Scholar
• HALLIWELL B: Free radicals, antioxidants, and humandisease: curiosity, cause, or consequence? Lancet (1994) 344:721–724.
   Google Scholar
• COHEN RA: The role of nitric oxide and otherendothelium-derived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis. (1995) )(XXVIII: 105–128.
   Google Scholar
• KEANEY JFJ, VITA JA Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog. Cardiovasc. Dis. (1995) 300(VIII:129–154.
   Google Scholar
• STEINBERG D, PARTHASARATHY S, CAREW TE et al.:Beyond cholesterol: Modification of low-density lipoprotein that increase its atherogenecity. N Engl. J. Med. (1989) 320:915–923.
   PubMed Web of Science ®Google Scholar
• NOUROOZ-ZADEH J, TAJADDINI-SARMADI J, WOLFF SP: Measurement of plasma hydroperoxide concentra-tions by the ferrous-oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal. Biochem. (1994) 220:403–409.
   PubMed Web of Science ®Google Scholar
• SAXENA U, GOLDBERG IJ: Endothelial cells and athero-sclerosis: lipoprotein metabolism, matrix interaction and monocyte recruitment. Curr. Opin. Lipid. (1994) 5:316–322.
   PubMedGoogle Scholar
• •The importance of LDL oxidation and monocyte recruitment in the vascular endothelium to the development of atherosclerosis.
   Google Scholar
• MUSLINER TA, KRAUSS RM: Lipoprotein subspecies and risk of coronary disease. Clin. Chem. (1988) 34:B78–B83.
   PubMed Web of Science ®Google Scholar
• RAJMAN I, MAXWELL S, CRAMB R et al.: Particle size: the key to the atherogenic lipoprotein? Q. J. Med. (1994) 87:709–720.
   Google Scholar
• RAJMAN I, EACHO PI, CHOWIENCZYK PJ et al.: LDL particle size: an important drug target? Br. J. Clin. Pharmacol. (1999) 48:125–133.
   Web of Science ®Google Scholar
• DEJAGER S, BRUKERT E, CHAPMAN MJ: Dense LDL subspecies with diminished oxidative resistance predominate in combined hyperlipidaemia. J. Lip. Res. (1993) 34:295–308.
   PubMed Web of Science ®Google Scholar
• BROWN MS, GOLDSTEIN JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposi-tion in atherosclerosis. Ann. Rev. Biochem. (1983) 52:223–261.
   PubMed Web of Science ®Google Scholar
• GERRITY RG: The role of the monocyte in athero-genesis. II. Migration of foam cells from atheroscle-rotic lesions. Am. J. Pathol (1981) 103:191–200.
   Google Scholar
• AQEL NM, BALL RY, WALDMAN H et al.: Monocytic origin of foam cells in human atherosclerotic plaques. Athero-sclerosis (1984) 53:265–271.
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis - an inflammatory disease. N Engl. J. Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• •This paper describes the inflammatory processes that are important in the development and progression of atherosclerosis.
   Google Scholar
• HOLVOET P: Role of oxidatively modified low density lipoproteins and anti-oxidants in atherothrombosis. Exp. Opin. Invest. drugs. (1999) 8:527–544.
   PubMedGoogle Scholar
• •A useful review of the scientific basis for anti-oxidant therapy in atherosclerotic disease.
   Google Scholar
• DAVIES MJ, RICHARDSON PD, WOOLF N et al.: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. (1993) 69:377–381.
   PubMedGoogle Scholar
• SCHORAH CJ: The transport of vitamin C and effects of disease. Proc. Nutr. Soc. (1992) 51:189–198.
   PubMed Web of Science ®Google Scholar
• KAYDEN HJ, TRABER MG: Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J. Lip. Res. (1993) 34:343–358.
   PubMed Web of Science ®Google Scholar
• BRAY TM, TAYLOR CG: Tissue glutathione, nutrition, and oxidative stress. Can. J. Physiol. Pharmacol. (1993) 71:746–751.
   PubMed Web of Science ®Google Scholar
• FREISLEBEN H-J, PACKER L: Free-radical scavenging activities, interactions and recycling of antioxidants. Biochem. Soc. Trans. (1993) 21:325–330.
   PubMed Web of Science ®Google Scholar
• PACKER JE, SLATER TF, WILSON RL: Direct observation of free radical interaction between vitamin E and vitamin C. Nature (1979) 278:737.
   PubMed Web of Science ®Google Scholar
• WINKLER BS, ORSELLI SM, REX TS: The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Rad. Biol. Medi. (1994) 17:333–349.
   PubMed Web of Science ®Google Scholar
• JANERO DR: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxida-tion and peroxidative tissue injury. Free Rad. Biol. Med. (1990) 9:515–540.
   PubMed Web of Science ®Google Scholar
• CRAMER GL, MILLER JF, PENDLETON RB et al.: Iodometric measurement of lipid hydroperoxides in human plasma. Analyt. Biochem. (1991) 193:204–211.
   PubMed Web of Science ®Google Scholar
• LYNCH SM, MORROW JD, ROBERTS LJII et al.: Formation of non-cyclooxygenase-derived prostanoids (F2.-isoprostanes) in plasma and low density lipopro-tein exposed to oxidative stress in vitro. J. Clin. Invest. (1994) 93:998–1004.
   Google Scholar
• RYAN M, OWENS D, KILBRIDE B et al.: Antibodies to oxidized lipoproteins and their relationship to myocardial infarction. Q. J. Med. (1998) 91:411–415.
   Google Scholar
• WAYNER DDM, BURTON GW, INGOLD KU et al: The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim. Biophys. Acta. (1987) 924:408–419.
   PubMed Web of Science ®Google Scholar
• DELANGE RJ, GLAZER AN: Phycoerythrin fluorescence-based assay for peroxy radicals: a screen for biologi-cally relevant protective agents. Analyt. Biochem. (1989) 177:300–306.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD TP, THORPE GHG, MAXWELL SRJ: Enhanced chemiluminescent assay for antioxidant capacity in biological fluids. Analyt. Chim. Acta. (1992) 266:265–277.
   Web of Science ®Google Scholar
• MILLER NJ, RICE-EVANS C, DAVIES MJ et al: A novel method for measuring antioxidant capacity and its application to measuring the antioxidant status in premature neonates. Clin. Sci. (1993) 84:407–412.
   PubMed Web of Science ®Google Scholar
• CAO G, VERDON CP, WU AHB et al.: Automated assay of oxygen radical absorbance capacity with the COBAS FARA II. Clin. Chem. (1995) 41:1738–1744.
   PubMed Web of Science ®Google Scholar
• NAGY E, DEGRELL I: Determination of ascorbic acid and dehydroascorbic acid in plasma and cerebro-spinal fluid by liquid chromatography with electro-chemical detection. J. Chromatogr. (1989) 497:276–281.
   PubMed Web of Science ®Google Scholar
• CAMMACK J, OKE A, ADAMS RN: Simultaneous high performance liquid chromatographic determination of ascorbic acid and dehydroascorbic acid in biological samples. J. Chromatogr. (1991) 565:529–532.
   PubMed Web of Science ®Google Scholar
• MILNE DB, BOTNEN J: Retinol,alpha-tocopherol,lycopene,alpha and beta-carotene simulta-neously determined in plasma by isocratic liquid chromatography. Clin. Chem. (1986) 32(5)874–876.
   Google Scholar
• BEUTLER E, GELBART T: Plasma glutathione in health and in patients with malignant disease. J. Lab. Gin. Med. (1985) 105:581–584.
   PubMed Web of Science ®Google Scholar
• HARVEY PRC, ILSON RG, STRASBURG SM: The simulta-neous determination of oxidised and reduced glutathione in liver tissue by ion pairing reverse phase high performance liquid chromatography with a coulimetric detector. Clin. Chim. Acta. (1989) 180:203–212.
   PubMed Web of Science ®Google Scholar
• MEFFEI FACINO R, CARINI M, ALDINI G etal.: Free radical scavenging action and anti-enzyme activities of procyanidins from vitis vinifera. Arzneim-Forsch/Drug Research (1994) 44:592–601.
   Google Scholar
• FRANKEL EN, KANNER J, GERMAN JB et al: Inhibition of oxidation of human low density lipoprotein by phenolic substances in red wine. Lancet (1993) 341:454-457. SIES H: Strategies of antioxidant defense. Eur. J. Biochem. (1993) 215:213-219. ESTERBAUER H, PUHL H, DIEBER-ROTHENEDER M et al: Effect of antioxidants on oxidative modification of LDL. Ann. Med. (1991) 23:573–581.
   Google Scholar
• ESTERBAUER H, GEBICKI J, PUHL H et al: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad. Biol. Med. (1992) 13:341–390.
   PubMed Web of Science ®Google Scholar
• DE WHALLEY CV, RANKIN SM, HOULT JRS et al.: Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem. Pharmacol. (1990) 39:1743–1750.
   PubMed Web of Science ®Google Scholar
• YUTING C, RONGLIANG Z, ZHONGJIAN J et al.: Flavonoids as superoxide scavengers and antioxi-dants. Free Rad. Biol. Med. (1990) 9:19–21.
   PubMed Web of Science ®Google Scholar
• DEMROW HS, SLANE PR, FOLTS JD: Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation (1995) 91:1182–1188.
   PubMed Web of Science ®Google Scholar
• RUF J-C, BERGER J-L, RENAUD S: Platelet rebound effect of alcohol withdrawal and wine drinking in rats. Relation to tannins and lipid peroxidation. Arterioscler. Thrombo. (1995) 15:140–144.
   Google Scholar
• WOLLNY T, AIELLO L, DI TOMMASO D et al.: Modulation of haemostatic function and prevention of experi-mental thrombosis by red wine: a role for increased nitric oxide production. Br. J. Pharmacol. (1999) 127:747–755.
   Google Scholar
• MAXWELL S, CRUICKSHANK A, THORPE G: Red wine and antioxidant activity in serum. Lancet (1994) 344:193–194.
   PubMed Web of Science ®Google Scholar
• ABU-AMSHA R, CROFT KD, PUDDEY IB et al: Phenolic content of various beverages determines the extent of human serum and low-density lipoprotein oxidation in vitro: identification and mechanism of some of cinnamic acid derivatives from red wine. Clin. Sci. (1996) 91:449–458.
   PubMed Web of Science ®Google Scholar
• SUZUKAWA M, ABBEY M, CLIFTON P et al.: Effects of supplementing with vitamin E on the uptake of low density lipoprotein and the stimulation of cholesteryl ester formation in macrophages. Atherosclerosis (1994) 110:77–86.
   PubMed Web of Science ®Google Scholar
• PORKKALA-SARATAHO E, NYYSSONEN K, SALONEN JT: Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men. Atherosclerosis (1996) 124:83–94.
   PubMed Web of Science ®Google Scholar
• MAXWELL SRJ, WIKLUND 0, BONDJERS G: Measurement of antioxidant activity in lipoproteins using enhanced chemiluminescence. Atherosclerosis (1994) 111:79–89.
   PubMed Web of Science ®Google Scholar
• MILLER N, PAGANGA G, WISEMAN S et al.: Total antioxi-dant activity of low density lipoproteins and the relationship with atocopherol status. FEBS Letts. (1995) 365:164–166.
   PubMed Web of Science ®Google Scholar
• JESSUP W, RANKIN SM, DE WHALLEY CV et al.: Alpha-tocopherol consumption during low-density-lipoprotein oxidation. Biochem. J. (1990) 265:399–405.
   Google Scholar
• ESTERBAUER H, STRIEGL G, PUHL H et al.: The role of vitamin E and carotenoids in preventing oxidation of low density lipoproteins. Ann. NY. Acad. Sci. (1989) 570:254–267.
   PubMed Web of Science ®Google Scholar
• DIEBER-ROTHENEDER M, PUHL H, WAEG G et al.: Effect of oral supplementation with D-a-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J. Lip. Res. (1991) 32:1325–1332.
   PubMed Web of Science ®Google Scholar
• JIALAL L, GRUNDY SM: Effect of dietary supplementa-tion with alpha-tocopherol on the oxidative modifica-tion of low density lipoprotein. J. Lip. Res. (1992) 33:899–906.
   PubMed Web of Science ®Google Scholar
• JIALAL I, FULLER CJ, HVET BA: The effect of alpha-tocopherol supplementation on LDL oxidation: a dose response study. Arterioscler. Thrombo. (1995) 15:190–198.
   PubMed Web of Science ®Google Scholar
• PRINCEN HMG, VAN POPPEL G, VOGELEZANG C et al.: Supplementation with vitamin E but not 8-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking. Arterioscler. Thrombo. (1992) 12:554–562.
   PubMedGoogle Scholar
• WILLIAMS RJ, MOTTERAM JM, SHARP CH et al.: Dietary vitamin E and the attenuation of early lesion develop-ment in modified Watanabe rabbits. Atherosclerosis (1992) 94:153–159.
   PubMed Web of Science ®Google Scholar
• WOJCICKI J, ROZEWICKA L, BARCEW-WISZNIEWSKA B et al.: Effect of selenium and vitamin E on the develop-ment of experimental atherosclerosis in rabbits. Atherosclerosis (1991) 87:9–16.
   PubMed Web of Science ®Google Scholar
• HODIS HN, MACK WJ, LABREE L et al.: Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atheroscle-rosis. JAMA (1995) 273:1849–1854.
   PubMed Web of Science ®Google Scholar
• JACOB RA: Vitamin C nutriture and risk of atheroscle-rotic heart disease. Nutr. Rev. (1998) 56:334–337.
   PubMed Web of Science ®Google Scholar
• ALLARD JP, ROYALL D, KURIAN R: Effects of beta-carotene supplementation on lipid peroxidation in humans. Am. J. Clin. Nutr. (1994) 59:884–890.
   PubMed Web of Science ®Google Scholar
• CARPENTER KL, VAN DER VEEN C, HIRD R: The carote-noids beta-carotene, canthaxanthin and zeaxanthin inhibit macrophage-mediated LDL oxidation. FEBS Letts. (1997) 401:262–266.
   PubMed Web of Science ®Google Scholar
• REAVEN PD, KHOUW A, BELTZ W et al.: Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not by 8-carotene. Arterioscler. Thrombo. (1993) 13:590–600.
   PubMed Web of Science ®Google Scholar
• NIKI E, NOGUCHI N, TSUCHIHASHI H et al.: Interaction among vitamin C, vitamin E, and 8-carotene. Am. J. Clin. Nutr. (1995) 62(Suppl.):1322S–1326S.
   Google Scholar
• JIALAL I, GRUNDY S: Preservation of the endogenous antioxidants in low-density lipoprotein by ascorbate but not probucol during oxidative modification. J. Clin. Investig. (1991) 87:597–601.
   PubMed Web of Science ®Google Scholar
• KAGAN VE, SERBINOVA EA, FONTE, T et al.: Recycling of vitamin E in human low-density lipoproteins. J. Lip. Res. (1992) 33:385–397.
   PubMed Web of Science ®Google Scholar
• MOSCA L, RUBENFIRE M, MANDEL C et al.: Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. J. Am. Coll. Cardiol (1997) 30:392–399.
   PubMed Web of Science ®Google Scholar
• ABBEY M, NESTEL PJ, BAGHURST PA: Antioxidant vitamins and low density lipoprotein oxidation. Am. J. Clin. Nutr. (1993) 58:525–532.
   PubMed Web of Science ®Google Scholar
• OHARA Y, PETERSON TE, HARRISON DG: Hypercholes-terolaemia increases endothelial superoxide anion production. J. Clin. Invest. (1994) 91:1057–1062.
   Google Scholar
• ANDERSSON TLG, MATZ J, FERNS GAA et al.: Vitamin E reverses cholsterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis (1994) 111:39045.
   Google Scholar
• KLEMSDAL TO, ANDERSSON TLG, MATZ J et al: Vitamin E restores endothelium-dependent vasodilatation in cholesterol-fed rabbits: in vivo measurements by photoplethysmography. Cardiovasc. Res. (1994) 28:1397–1402.
   PubMed Web of Science ®Google Scholar
• GREEN D, O'DRISCOLL G, RANKIN JM et al.: Beneficial effect of vitamin E administration on nitric oxide function in subjects with hypercholesterolaemia. Sci. (1998) 95:361–367.
   Google Scholar
• •Modification of nitric oxide release with vitamin E supple-mentation in patients with hypercholesterolaemia.
   Google Scholar
• GOKCE N, KEANEY JFJ, FRET B et al: Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation (1999) 99:3234–3240.
   PubMed Web of Science ®Google Scholar
• •Evidence of improved endothelial function after regular vitamin C supplementation in humans.
   Google Scholar
• PLOTNICK GD, CORRETTI MC, VOGEL RA: Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA (1997) 278:1682–1686.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ, EIKELBOOM JW: Homocysteine and vascular disease. Lancet (1999) 354:407–413.
   PubMed Web of Science ®Google Scholar
• LOSCALZO J: The oxidant stress of hyperhomo-cyst(e)inemia. j Clin. Invest. (1996) 98:5–7.
   PubMed Web of Science ®Google Scholar
• NAPPO F, DE ROSA N, DE LUCIA D et al.: Impairment of endothelial functions by acute hyperhomocystene-inemia and reversal by antioxidant vitamins. JAMA (1999) 281:2113–2118.
   Google Scholar
• •Suggests an asociation between homocysteine-derived free radical production and endothelial dysfunction.
   Google Scholar
• NUTTALL SL, KENDALL MJ, BOMBARDELLI E et al.: An evaluation of the antioxidant activity of a standardized grape seed extract Leucoselect. J. Clin. Pharm. Ther. (1998) 23:385–389.
   PubMed Web of Science ®Google Scholar
• MAFFEI FACINO R, CARINI M, ALDINI G et al.: Sparing effect of procyanidins from vitis vinifera on vitamin E: in vitro studies. Planta Medica (1998) 64:343–347.
   PubMed Web of Science ®Google Scholar
• NUTTALL SL, KENDALL MJ, MARTIN U: Antioxidant therapy for the prevention of cardiovascular disease. Q. J. Med. (1999) 92:239–244.
   Google Scholar
• PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. (1996) 334:1349–1355.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, GILBERT EM, ABRAHAM WT: Carvedilol produces dose-related improvements in left ventricular function and survival in sujects with chronic heart failure. Circulation (1996) 94:2807–2816.
   PubMed Web of Science ®Google Scholar
• KUKIN ML, KALMAN J, CHARNEY RH et al.: Prosper-tive,randomised comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation (1999) 99:2645–2651.
   PubMed Web of Science ®Google Scholar
• FERRARI R, AGNOLETTI L, COMINI L et al.: Oxidative stress during myocardial ischaemia and heart failure. Eur. Heart J. (1998) 19 (Suppl. 13):B2–B11.
   Google Scholar
• MCMURRAY J, MCLAY J, CHOPRA MB et al.: Evidence for enhanced free radical acitivity in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. (1990) 65:1261–1262.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, CHOPRA MB, ABDULLAH I et al.: Evidence of oxidative stress in chronic heart failure in humans. Eur. Heart J. (1993) 14:1493–1498.
   PubMed Web of Science ®Google Scholar
• YUE T-L, CHENG H-Y, LYSKO PG et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol Exp. Ther. (1992) 263:92–98.
   PubMed Web of Science ®Google Scholar
• LOPEZ BL, CHRISTOPHER TA, YUE T-L et al.: Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology (1995) 51:165–173.
   PubMed Web of Science ®Google Scholar
• MAGGI E, MARCHESI E, COVINI D et al.: Protective effects of carvedilol, a vasodilating p-adrenoceptor blocker, against in vivo low denity lipoprotein oxidation in essential hypertension. J. Cardiov. Pharmacol. (1996) 27:532–538.
   PubMed Web of Science ®Google Scholar
• FEUERSTEIN GZ, RUFFOLO RR: Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur. Heart J. (1996) 17 (Suppl. B):24-29. CLELAND JGF, MCGOWAN J, CLARK A: The evidence for pblockers in heart failure. Br. Med. J. (1999) 318:824-825. KENDALL MJ, TOESCU V: Non-lipid properties of statins. J. Clin. Pharm. Ther. (1999) 24(1):3–5. VAUGHAN CJ, MURPHY MB, BUCKLEY BM: Statins do more than just lower cholesterol. Lancet (1996) 348:1079–1082.
   Google Scholar
• HOFFMAN R, BROOK GJ, AVIRAM M: Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and in vivo studies. Athero-sclerosis (1992) 93:105–113.
   PubMed Web of Science ®Google Scholar
• GIROUX LM, DAVIGNON J, NARUSZEWICZ M: Simvas-tatin inhibits the oxidation of low-density lipopro-teins by activated human monocyte-derived macrophages. Biochim. Biophys. Acta. (1 9 9 3) 1165:335–338.
   Google Scholar
• HUSSEIN 0, SCHLEZINGER S, ROSENBLAT M et al.: Reduced susceptibility of low-density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolaemic effect of the drug and its binding to the LDL. Atherosclerosis (1997) 128:11–18.
   Google Scholar
• KUZUYA M, KUZUYA F: Probucol as an antioxidants and antiatherigenic drug. Free Rad. Biol. Med. (1993) 14:67–77.
   PubMed Web of Science ®Google Scholar
• REAVEN PD, PARTHASARATHY S, BELT WF et al.: Effect of probucol doasge on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler. Thrombo. (1992) 12:318–324.
   PubMed Web of Science ®Google Scholar
• FENG Y-H, HART G: Suppression of oxidant production by diltiazem, nifedipine and verapamil in human neutrophils. Clin. ScL (1996) 91:459–466.
   PubMed Web of Science ®Google Scholar
• BAGCHI D, PRASAD R, DAS DK: Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem. Biophys. Res. Commun. (1989) 158:52–57.
   PubMed Web of Science ®Google Scholar
• CHOPRA M, SCOTT N, MCMURRAY J et al.: Captopril: a free radical scavenger. Br. J. Clin. Pharmacol (1989) 27:396–399.
   PubMed Web of Science ®Google Scholar
• LAPENNA D, DE GIOIA, CIOFANI G et al.: Captopril has no significant scavenging antioxidant activity in human plasma in vitro or in vivo. Br. J. Orin. Pharmacol. (1996) 42:451–456.
   PubMed Web of Science ®Google Scholar
• ENSTROM JE, KANIM LE, KLEIN MA: Vitamin C intake and mortality among a sample of the United States popula-tion. Epidemiology (1992) 3:194–202.
   PubMed Web of Science ®Google Scholar
• LOSONCZY KG, HARRIS TB, HAVLIK RJ: Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am. J. Clin. Nutr. (1996) 64:190–196.
   PubMed Web of Science ®Google Scholar
• GEY KF, PUSKA P, JORDAN P et al.: Inverse correlation between plasma vitamin E and mortality from ischaemic heart disease in cross-cultural epidemi-ology. Am. J. Clin. Nutr. (1991) 53:326S–334S.
   Google Scholar
• NYYSSONEN K, PARVIAINEN MT, SALONEN R et al: Vitamin C deficiency and risk of myocardial infarc-tion: prospective population study of men from eastern Finland. Br. Med. J. (1997) 314:634–638.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, HENNEKENS CH, MANSON JE et al.: Vitamin E consumption and the risk of coronary heart disease in women. N Engl. J. Med. (1993) 328:1444–1449.
   PubMed Web of Science ®Google Scholar
• RIMM EB, STAMPFER MJ, ASCHERIO A et al.: Vitamin E consumption and the risk of coronary heart disease in men. N Engl. J. Med. (1993) 328:1450–1456.
   PubMed Web of Science ®Google Scholar
• STEPHENS N, PARSONS A, SCHOFIELD P et al.: Random-ised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet (1996) 347:781–786.
   PubMed Web of Science ®Google Scholar
• •Regular consumption of vitamin E (400 and 800 IU) was associated with a significant reduction in coronary events.
   Google Scholar
• STEPHENS N: Antioxidant therapy for ischaemic heart disease:where do we stand? Lancet (1997) 349: 1710-1711.
   Google Scholar
• GALE CR, MARTYN CN, WINTER PD et al.: Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. Br. Med. J. (1995) 310:1563–1566.
   PubMed Web of Science ®Google Scholar
• THE A-TOCOPHEROL, BCCPSG: The effect of vitamin E and Beta Carotene on the incidence of lung cancer and other cancers in male smokers. N Engl. J. Med (1994) 330:1029–1035.
   PubMed Web of Science ®Google Scholar
• OMENN GS, GOODMAN GE, THORNQUIST MD et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl. J. Med (1996) 334:1150–1155.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, BURING JE, MANSON JE et al.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New Engl. J. Med. (1996) 334:1145–1149.
   PubMed Web of Science ®Google Scholar